JAMDA
Volume 11, Issue 9 , Pages 636-644.e1 , November 2010

Memantine Discontinuation and the Health Status of Nursing Home Residents With Alzheimer's Disease

  • Howard Fillit, MD

      Affiliations

    • Brookdale Department of Geriatrics and Adult Development, The Mount Sinai School of Medicine, New York, NY, and the Alzheimer's Drug Discovery Foundation
    • Corresponding Author InformationAddress correspondence to Howard Fillit, MD, Alzheimer's Drug Discovery Foundation, 1414 Avenue of the Americas, Suite 1502, New York, NY 10019.
    • ,
  • Robert K. Hofbauer, PhD

      Affiliations

    • Forest Research Institute, Jersey City, NJ
    • ,
  • Juliana Setyawan, PharmD, MS

      Affiliations

    • formerly at Forest Research Institute, Inc, currently employed by Shire Pharmaceuticals, Inc., Wayne, PA
    • ,
  • Stavros Tourkodimitris, PhD

      Affiliations

    • Forest Research Institute, Jersey City, NJ
    • ,
  • Moshe Fridman, PhD

      Affiliations

    • AMF Consulting, Los Angeles, CA
    • ,
  • Vojislav Pejović, PhD

      Affiliations

    • Prescott Medical Communications Group, Inc., Chicago, IL
    • ,
  • Michael L. Miller, PhD

      Affiliations

    • Prescott Medical Communications Group, Inc., Chicago, IL
    • ,
  • M. Haim Erder, PhD

      Affiliations

    • formerly at Forest Research Institute, Inc, currently employed by Shire Pharmaceuticals, Inc., Wayne, PA
    • ,
  • Constantine Lyketsos, MD, MHS

      Affiliations

    • Johns Hopkins University and Johns Hopkins Bayview Medical Center, Baltimore, MD

References 

  1. Magaziner J, German P, Zimmerman SI, et al. The prevalence of dementia in a statewide sample of new nursing home admissions aged 65 and older: diagnosis by expert panel. Epidemiology of Dementia in Nursing Homes Research Group Gerontologist. 2000;40:663–672
  2. Neumann PJ, Araki SS, Arcelus A, et al. Measuring Alzheimer's disease progression with transition probabilities: Estimates from CERAD. Neurology. 2001;57:957–964
  3. Oliveria SA, Liperoti R, L'Italien G, et al. Adverse events among nursing home residents with Alzheimer's disease and psychosis. Pharmacoepidemiol Drug Saf. 2006;15:763–774
  4. Black BS, Finucane T, Baker A, et al. Health problems and correlates of pain in nursing home residents with advanced dementia. Alzheimer Dis Assoc Disord. 2006;20:283–290
  5. Brodaty H, Draper BM, Millar J, et al. Randomized controlled trial of different models of care for nursing home residents with dementia complicated by depression or psychosis. J Clin Psychiatry. 2003;64:63–72
  6. Covinsky KE, Eng C, Lui LY, et al. The last 2 years of life: Functional trajectories of frail older people. J Am Geriatr Soc. 2003;51:492–498
  7. Field TS, Gurwitz JH, Avorn J, et al. Risk factors for adverse drug events among nursing home residents. Arch Intern Med. 2001;161:1629–1634
  8. Fitz D, Mallya A. Discontinuation of a psychogeriatric program for nursing home residents: Psychotropic medication changes and behavioral reactions. J Appl Gerontol. 1992;11:50–63
  9. Gerety MB, Cornell JE, Plichta DT, Eimer M. Adverse events related to drugs and drug withdrawal in nursing home residents. J Am Geriatr Soc. 1993;41:1326–1332
  10. Raivio MM, Laurila JV, Strandberg TE, et al. Use of inappropriate medications and their prognostic significance among in-hospital and nursing home patients with and without dementia in Finland. Drugs Aging. 2006;23:333–343
  11. Van Dijk PT, Dippel DW, Van Der Meulen JH, Habbema JD. Comorbidity and its effect on mortality in nursing home patients with dementia. J Nerv Ment Dis. 1996;184:180–187
  12. Cohen-Mansfield J, Lipson S, Werner P, et al. Withdrawal of haloperidol, thioridazine, and lorazepam in the nursing home: A controlled, double-blind study. Arch Intern Med. 1999;159:1733–1740
  13. Ballard C, Hanney ML, Theodoulou M, et al. The dementia antipsychotic withdrawal trial (DART-AD): Long-term follow-up of a randomised placebo-controlled trial. Lancet Neurol. 2009;8:151–157
  14. Mintzer JE, Tune LE, Breder CD, et al. Aripiprazole for the treatment of psychoses in institutionalized patients with Alzheimer dementia: A multicenter, randomized, double-blind, placebo-controlled assessment of three fixed doses. Am J Geriatr Psychiatry. 2007;15:918–931
  15. Streim JE, Porsteinsson AP, Breder CD, et al. A randomized, double-blind, placebo-controlled study of aripiprazole for the treatment of psychosis in nursing home patients with Alzheimer disease. Am J Geriatr Psychiatry. 2008;16:537–550
  16. Parsons CG, Stöffler A, Danysz W. Memantine: A NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system—too little activation is bad, too much is even worse. Neuropharmacology. 2007;53:699–723
  17. McShane R, Areosa Sastre A, Minakaran N. Memantine for dementia. Cochrane Database Syst Rev. 2006;2:CD003154
  18. Cummings JL, Olin JT. Meta-analysis of neuropsychiatric inventory (NPI) domains in three 6-month trials of memantine in moderate to severe AD. Alzheimer's & Dementia. 2006;2:S231
  19. Cummings JL, Schneider E, Tariot PN, Graham SM. Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment. Neurology. 2006;67:57–63
  20. Feldman HH, Schmitt FA, Olin JT. Activities of daily living in moderate-to-severe Alzheimer disease: An analysis of the treatment effects of memantine in patients receiving stable donepezil treatment. Alzheimer Dis Assoc Disord. 2006;20:263–268
  21. Gauthier S, Loft H, Cummings J. Improvement in behavioural symptoms in patients with moderate to severe Alzheimer's disease by memantine: A pooled data analysis. Int J Geriatr Psychiatry. 2008;23:537–545
  22. Gauthier S, Wirth Y, Möbius HJ. Effects of memantine on behavioural symptoms in Alzheimer's disease patients: An analysis of the Neuropsychiatric Inventory (NPI) data of two randomised, controlled studies. Int J Geriatr Psychiatry. 2005;20:459–464
  23. Hofbauer RK, Saxton J, Woodward M, et al. Effects of memantine on functional communication in patients with moderate AD: Results of a 12-week placebo-controlled trial. Alzheimers Dement. 2009;5:P256–P257
  24. Winblad B, Poritis N. Memantine in severe dementia: Results of the 9M-Best Study (Benefit and efficacy in severely demented patients during treatment with memantine). Int J Geriatr Psychiatry. 1999;14:135–146
  25. Kwak YT, Han IW, Suk SH, Koo MS. Two cases of discontinuation syndrome following cessation of memantine. Geriatr Gerontol Int. 2009;9:203–205
  26. Alzheimer's Association. 2009 Alzheimer's disease facts and figures. Alzheimers Dement. 2009;5:234–270
  27. Hebert LE, Scherr PA, Bienias JL, et al. Alzheimer disease in the US population: Prevalence estimates using the 2000 census. Arch Neurol. 2003;60:1119–1122
  28. Hebert LE, Scherr PA, Bienias JL, et al. State-specific projections through 2025 of Alzheimer disease prevalence. Neurology. 2004;62:1645
  29. Geldmacher DS, Frolich L, Doody RS, et al. Realistic expectations for treatment success in Alzheimer's disease. J Nutr Health Aging. 2006;10:417–429
  30. Lanctôt K, Eryavec G, Herrmann N. Treatment with memantine improves nursing care burden in severe Alzheimer's disease. International Psychogeriatrics. 2009;21(suppl 2):S110
  31. Schmitt FA, Wichems CH. A systematic review of assessment and treatment of moderate to severe Alzheimer's disease. Prim Care Companion J Clin Psychiatry. 2006;8:158–159
  32. Tariot P. Contemporary issues in the treatment of Alzheimer's disease: Tangible benefits of current therapies. J Clin Psychiatry. 2006;67:15–22
  33. Hawes C, Morris JN, Phillips CD, et al. Reliability estimates for the Minimum Data Set for nursing home resident assessment and care screening (MDS). Gerontologist. 1995;35:172–178
  34. Morrison DF. Multivariate Statistical Methods. 3rd ed.. New York: McGraw-Hill; 1990;
  35. Hatcher LA. Step-by-step approach to using the SAS system for factor analysis and structural equation modeling. Cary, NC: SAS Institute; 1994;
  36. Morris JN, Fries BE, Mehr DR, et al. MDS Cognitive Performance Scale. J Gerontol. 1994;49:M174–M182
  37. Fillit HM, Futterman R, Orland BI, et al. Polypharmacy management in Medicare managed care: Changes in prescribing by primary care physicians resulting from a program promoting medication reviews. Am J Manag Care. 1999;5:587–594
  38. Herrmann N, Gauthier S. Diagnosis and treatment of dementia: 6. Management of severe Alzheimer disease. CMAJ. 2008;179:1279–1287
  39. Gauthier S. Managing discontinuation syndrome in patients with dementia. J Psychiatry Neurosci. 2006;31:72
  40. Fillit HM, Doody RS, Binaso K, et al. Recommendations for best practices in the treatment of Alzheimer's disease in managed care. Am J Geriatr Pharmacother. 2006;4(Suppl A):S9–S24quiz S25–S28
  41. Doody RS, Tariot PN, Pfeiffer E, et al. Meta-analysis of six-month memantine trials in Alzheimer's disease. Alzheimers Dement. 2007;3:7–17
  42. Grossberg GT, Pejovic V, Miller ML, Graham SM. Memantine therapy of behavioral symptoms in community-dwelling patients with moderate to severe Alzheimer's disease. Dement Geriatr Cogn Disord. 2009;27:164–172
  43. Fillit H, Hofbauer RK, Setyawan J, et al. Memantine discontinuation in nursing home residents with Alzheimer's disease is associated with an increase in Alzheimer's disease symptoms [abstract]. Alzheimers Dement. 2008;4:T663
  44. Olin JT, Bhatnagar V, Reyes P, et al. Safety and tolerability of rivastigmine capsule with memantine in patients with probable Alzheimer's disease: a 26-week, open-label, prospective trial (Study ENA713B US32). Int J Geriatr Psychiatry. 2010;25:419–426
  45. Daiello LA, Ott BR, Lapane KL, et al. Effect of discontinuing cholinesterase inhibitor therapy on behavioral and mood symptoms in nursing home patients with dementia. Am J Geriatr Pharmacother. 2009;7:74–83

 Ron Weishaar, PhD, and the staff at Omnicare Clinical Research (King of Prussia, PA) participated in protocol consultations and data collection. E. Malca Resnick, PhD, participated in the study conceptualization/design, conduct, and initial analyses. This study was sponsored by Forest Laboratories, Inc, which included providing financial, material, and statistical support.

PII: S1525-8610(09)00522-2

doi: 10.1016/j.jamda.2009.12.086

JAMDA
Volume 11, Issue 9 , Pages 636-644.e1 , November 2010

Article Tools

* Image Usage & Resolution